Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.48)
# 254
Out of 4,757 analysts
78
Total ratings
56.36%
Success rate
20.12%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWTX SpringWorks Therapeutics | Maintains: Outperform | $60 → $65 | $51.32 | +26.66% | 2 | Feb 12, 2025 | |
| MRNA Moderna | Maintains: In-Line | $60 → $50 | $34.30 | +45.77% | 5 | Jan 27, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $32.23 | +55.13% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $28.13 | +77.75% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $110.83 | +12.79% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $71.21 | +47.45% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $698.44 | +68.23% | 5 | Oct 24, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $68.60 | +23.91% | 1 | May 14, 2024 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $175 | $112.66 | +55.33% | 1 | May 14, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $84 → $88 | $40.02 | +119.89% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $147.37 | +87.28% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $2.55 | +1,272.55% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,520 → $780 | $4.11 | +18,878.10% | 5 | Feb 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $317.82 | -27.00% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $70.09 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $116.04 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $34.65 | -39.39% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $3.62 | +536.24% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $14.34 | +1,643.38% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $0.37 | +2,619.61% | 1 | Feb 14, 2018 |
SpringWorks Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $51.32
Upside: +26.66%
Moderna
Jan 27, 2025
Maintains: In-Line
Price Target: $60 → $50
Current: $34.30
Upside: +45.77%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $32.23
Upside: +55.13%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $28.13
Upside: +77.75%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $110.83
Upside: +12.79%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $71.21
Upside: +47.45%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $698.44
Upside: +68.23%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $68.60
Upside: +23.91%
Neurocrine Biosciences
May 14, 2024
Initiates: Outperform
Price Target: $175
Current: $112.66
Upside: +55.33%
Ultragenyx Pharmaceutical
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $40.02
Upside: +119.89%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $147.37
Upside: +87.28%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $2.55
Upside: +1,272.55%
Feb 17, 2021
Downgrades: Neutral
Price Target: $1,520 → $780
Current: $4.11
Upside: +18,878.10%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $317.82
Upside: -27.00%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $70.09
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $116.04
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $34.65
Upside: -39.39%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $3.62
Upside: +536.24%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $14.34
Upside: +1,643.38%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $0.37
Upside: +2,619.61%